Back to top

Biotechnology Ultra Sector Pro F: (MF: BIPSX)

(MF) As of Apr 17, 2014 06:05 PM ET

 Add to portfolio

$38.53 USD

+0.06 (0.16%)

Zacks MF Rank : 1 - Strong Buy [?] 1        

This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Fund's over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Mutual Fund Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank

General Information as of Mar 31, 2014

% Yield 0.00
% SEC Yield NA
% YTD Return (as of Mar 31, 2014) -0.16
Objective* Equity - Sector Health
Peer* HL LG

*Key

Zacks Premium Research for BIPSX

This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Fund's over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Mutual Fund Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank

Zacks MF Rank [?] Rank Change Trend Strong Buy 1
MF Research Report

( = Change in last 30 days)

Zacks Mutual Fund #1 Ranked Funds

View the Zacks Mutual Fund Rank Guide

Portfolio Statistics

%Unrealized Gain YTD 16.76
Net Assets (Mil $) 3/31/2014 25.30
%Turnover 3/31/2014 14.00

Allocation

% of Portfolio
Large Growth NA
Large Value NA
Small Growth NA
Small Value NA
Foreign Stock NA
Emerging Market NA
Precious Metal NA
Intermediate Bond NA
Foreign Bond NA
High Yield Bond NA

Sector / Country Weightings

As of 3/31/2014 % of Portfolio
Other 43.83
Health 29.61
Services 15.93
Industrial Cyclical 7.89
Technology 2.74

Portfolio Holdings

Top Equity Holdings
(As of 1/31/2014)
% of Portfolio Value (Mil$)
GILEAD SCIENCES INC 13.26 74.12
AMGEN INC 9.62 53.80
ABBVIE INC 8.39 46.91
BIOGEN IDEC INC 7.89 44.13
CELGENE CORP 6.71 37.53
ALEXION PHARMACEUTICALS I 3.32 18.59
REGENERON PHARMACEUTICALS 2.40 13.42
ILLUMINA INC 2.05 11.46
VERTEX PHARMACEUTICALS IN 1.97 11.03

Stock Holding % of Net Assets

As Of 1/31/2014
Total Issues 27
Avg. P/E 42.58
Avg. P/Book 6.04
Avg. EPS Growth 15.81
Avg. Market Value (Mil $) 67,873

Risk

3 Year 5 Year 10 Year
Beta 1.38 1.12 1.03
Alpha 29.65 11.71 11.52
R Squared 0.39 0.33 0.29
Std. Dev. 27.56 27.33 28.15
Sharpe 2.08 1.44 3.00